Rilematovir|1383450-81-4|(JNJ-678; JNJ-53718678)-陌孚医药/Medlife

您当前的位置：

Rilematovir (Synonyms: JNJ-678; JNJ-53718678)

目录号: PL11093 纯度: ≥98%

CAS No. :1383450-81-4

商品编号	规格	价格	会员价
PL11093-5mg	5mg	¥618.18	请登录
PL11093-10mg	10mg	¥1050.91	请登录
PL11093-25mg	25mg	¥2225.45	请登录
PL11093-50mg	50mg	¥3832.73	请登录
PL11093-100mg	100mg	¥6676.36	请登录
PL11093-200mg	200mg	询价	询价
PL11093-500mg	500mg	询价	询价
PL11093-10mM*1mLinDMSO	10mM*1mLinDMSO	¥681.24	请登录

Medlife所售产品仅用于科学研究（非临床研究），非药品不可食用，不可用于人体或动物的临床诊断和治疗，我们不为个人提供产品及服务。产品COA等资料，可至下方“质量控制”中下载。

加入购物车在线咨询收藏产品大包装询价

中文名称	Rilematovir
中文别名	3-((5-Chloro-1-(3-(methylsulfonyl)propyl)-1H-indol-2-yl)methyl)-1-(2,2,2-trifluoroethyl)-1H-imidazo[4,5-c]pyridin-2(3H)-one
英文名称	Rilematovir
英文别名	3-((5-Chloro-1-(3-(methylsulfonyl)propyl)-1H-indol-2-yl)methyl)-1-(2,2,2-trifluoroethyl)-1H-imidazo[4,5-c]pyridin-2(3H)-one;3-[[5-Chloranyl-1-(3-Methylsulfonylpropyl)indol-2-Yl]methyl]-1-[2,2,2-Tris(Fluoranyl)ethyl]imidazo[4,5-C]pyridin-2-One;NQ99E8OH3P;GTQTUABHRCWVLL-UHFFFAOYSA-N;6YA;3-[[5-Chloro-1-(3-methylsulfonylpropyl)indol-2-yl]methyl]-1-(2,2,2-trifluoroethyl)imidazo[4,5-c]pyri;Rilematovir;Rilematovir [INN];3-((5-Chloro-1-(3-methylsulfonylpropyl)indol-2-yl)methyl)-1-(2,2,2-trifluoroethyl)imidazo(4,5-C)pyridin-2-one;2H-Imidazo(4,5-;Unii-NQ99E8OH3P;3-((5-chloro-1-(3-(methylsulfonyl)propyl)-1H-indol-2-yl)methyl)-1-(2,2,2-trifluoroethyl)-1,3-dihydro-2H-imidazo[4,5-c]pyridin-2-one;C(CCN1C(=CC2=CC(=CC=C12)Cl)CN1C2=C(N(C1=O)CC(F)(F)F)C=CN=C2)S(=O)(=O)C;2H-Imidazo(4,5-C)pyridin-2-one, 3-((;JNJ-678;JNJ-53718678
Cas No.	1383450-81-4
分子式	C₂₁H₂₀ClF₃N₄O₃S
分子量	500.92
包装储存	Powder -20°C 3 years；4°C 2 years

产品详情

Rilematovir (JNJ-678) 是新型融合蛋白 (fusion protein) 抑制剂，有潜力用于呼吸道合胞病毒 (RSV)的研究。

生物活性

Rilematovir (JNJ-678) is a novel fusion protein inhibitor. Rilematovir has the potential for respiratory syncytial virus (RSV) research.

性状

Solid

IC50 & Target[1][2]

Fusion protein

体外研究(In Vitro)

Rilematovir is a small-molecule respiratory syncytial virus (RSV) fusion inhibitor currently under clinical evaluation in infants hospitalized for RSV infection. Rilematovir binds to RSV F protein in its prefusion conformation. Rilematovir displays very potent antiviral activity and low cytotoxicity. In addition to its activity against the RSV A2 strain, Rilematovir is also highly active against a number of RSV strains from both A and B subtypes. The EC50 in an RSV infection assay using HeLa cells is 460?pM. has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究(In Vivo)

Oral treatment of neonatal lambs with Rilematovir, or with an equally active close analog, efficiently inhibits established acute lower respiratory tract infection in the animals, even when treatment is delayed until external signs of respiratory syncytial virus illness have become visible. has not independently confirmed the accuracy of these methods. They are for reference only.

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Powder -20°C 3 years；4°C 2 years

ClinicalTrial

参考文献

[1]. Roymans D, et al. Therapeutic efficacy of a respiratory syncytial virus fusion inhibitor. Nat Commun. 2017 Aug 1;8(1):167.

溶解度数据	In Vitro: DMSO : 65 mg/mL (129.76 mM; Need ultrasonic)配制储备液

搜索质检报告(COA)

产品使用指南

Data Sheet

1：一般建议：溶解度为Medlife测试数据，可能与文献描述存在差异。这是由于生产工艺和批次不同产生的正常现象。为了使其更好的溶解，请用37℃加热试管并在超声波水浴中震动片刻。不同批次产品溶解度各有差异，仅做参考，具体以实验方案为准。

2：储存条件：粉末-20°C一般情况可以保存3年，溶于溶剂-80°C一般情况可以保存1年。不同产品及不同批次产品可能存在差异，请细致阅读产品信息，并辅助参考相关文献描述。

相关产品

The molarity calculator equation

The dilution calculator equation